Knowledge provided under the scope of this study can form the basis for the targeted development of designer peptides that would bind to the HLA-E expressed on the target cell surface and abrogate the NKG2A/CD94+ immune cell inhibition, over pronounced in some pathological conditions and in senescent cell accumulation, potentially leading to new cancer immunotherapies as well as new treatment of age-related diseases, by modulating the number of senescent cells. This evidence concerns the gene KLRC1 and cancer.